An alternative approach, termed GeneRide (23, 36), has been developed for genome editing in metabolic disorders, which delivers a donor vector containing a promoterless transgene (with or with CRISPR/Cas9) to integrate in the Alb locus and drive high hepatic expression. This evidence concerns the gene ALB and metabolic disease.